Lymphoma
Conditions
Brief summary
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Detailed description
Primary Objective: • To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas. Secondary Objectives: * To provide useful prognostic information before treatment, assess molecular response at interim time points and residual disease at the end of therapy, and identify tumor-specific mutations * Levels of cfDNA and its association with both EFS and OS in patients receiving therapy
Interventions
DIAGNOSTIC_TESTcell-free DNA
Given by IV (vein)
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male/female patients who are at least 18 years of age on the day of informed consent signing. 2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy. 3. Provision of written informed consent for the study. 4. Pregnant women not included 5. Cognitively impaired adults are not included.
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | through study completion; an average 1 year |
Countries
United States
Contacts
CONTACTChijioke Nze, MD
PRINCIPAL_INVESTIGATORChijioke Nze, MD
M.D. Anderson Cancer Center
Outcome results
None listed